A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.
Checked against the public recordLast updated Jun 27, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Pfizer
- Interventions being studied
- Drug: sunitinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Must have ended treatment from one of the following sunitinib studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future. Exclusion Criteria: * See inclusion criteria
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Emory University, Winship Cancer InstituteAtlanta, Georgia
- Investigational Drug ServiceAtlanta, Georgia
- The Emory ClinicAtlanta, Georgia
- Loyola University Medical CenterMaywood, Illinois
- University of Iowa Hospitals and ClinicsIowa City, Iowa
- Siteman Cancer CenterCity of Saint Peters, Missouri
- Siteman Cancer Center-West CountyCreve Coeur, Missouri
- Barnes Jewish HospitalSt Louis, Missouri
- Washington University School of Medicine, Siteman Cancer CenterSt Louis, Missouri
- Comprehensive Cancer Center of NevadaLas Vegas, Nevada
- Comprehensive Cancer Centers of NevadaLas Vegas, Nevada
- Northwest Cancer Specialists, P.C.Portland, Oregon
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 27, 2019. Always confirm current availability with the study team.